In a report released today, Jamie Perse from Goldman Sachs maintained a Hold rating on Lifestance Health Group (LFST – Research Report). The company’s shares closed yesterday at $6.20.
According to TipRanks, Perse is an analyst with an average return of -3.2% and a 34.21% success rate. Perse covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Tenet Healthcare, and Agilon Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lifestance Health Group with a $10.00 average price target.
See the top stocks recommended by analysts >>
Based on Lifestance Health Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $259.58 million and a GAAP net loss of $45.48 million. In comparison, last year the company earned a revenue of $209.53 million and had a GAAP net loss of $68.73 million
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lifestance Health Group (LFST) Company Description:
LifeStance Health Group Inc is a providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. The company delivers personalized, data-driven and comprehensive care to help patients stay healthy and employs over 3,300 psychiatrists, advanced practice nurses, psychologists and therapists.
Read More on LFST:
- LifeStance Reports Third Quarter 2023 Results
- Morgan Stanley Predicts at Least 70% Upside for These 2 High-Conviction Stocks — They Have Upcoming Catalysts and Strong Growth Prospects
- Morgan Stanley positive on LifeStance ahead of earnings
- Morgan Stanley sees ‘compelling entry point’ after LifeStance targeted by shorts
- LifeStance ‘represents the worst of the public markets,’ says The Bear Cave
